Envoy Medical, Inc. — fact timeline

Envoy Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 19, 2026, the Company received a second staff notification from Nasdaq informing the Company that, although the Company had not met the Bid Price Requirement by the Compliance Date, the Company is eligible for an add”

Envoy Medical, Inc. shareholders approved Approval for the purposes of complying with Nasdaq Listing Rule 5635(d) of the issuance of warrants to purchase shares of Common Stock and the issuance of Class A Common Stock underlying such warrants issued in a transaction completed on February 12, 2026 at the 2026-05-18 meeting.

“6. Stockholders approved, for the purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of warrants to purchase shares of the Common Stock, and the issuance of Class A Common Stock underlying such warrants, that were issued in a transaction that was completed on February 12, 2026.”

Envoy Medical, Inc. shareholders approved Amendment to the Employee Stock Purchase Plan to authorize an additional 1,200,000 shares of Common Stock for issuance under such plan at the 2026-05-18 meeting.

“5. Stockholders approved an amendment to the Employee Stock Purchase Plan to authorize an additional 1,200,000 shares of Common Stock for issuance under such plan;”

Envoy Medical, Inc. shareholders approved Amendment to the Equity Incentive Plan to authorize an additional 6,000,000 shares of Common Stock for issuance under such plan at the 2026-05-18 meeting.

“4. Stockholders approved an amendment to the Equity Incentive Plan to authorize an additional 6,000,000 shares of Common Stock for issuance under such plan;”

Envoy Medical, Inc. shareholders approved Approval, on a non-binding and advisory basis, of the compensation of the Company's named executive officers at the 2026-05-18 meeting.

“3. Stockholders approved, on a non-binding and advisory basis, the compensation of the Company’s named executive officers;”

Envoy Medical, Inc. shareholders approved Ratification of the appointment of EisnerAmper, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-18 meeting.

“2. Stockholders ratified the appointment of EisnerAmper, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026;”

Envoy Medical, Inc. shareholders approved Election of two Class III director nominees, Brent T. Lucas and Susan J. Kantor at the 2026-05-18 meeting.

“1. The Company’s stockholders elected two Class III director nominees, Brent T. Lucas and Susan J. Kantor, to the Company’s Board of Directors to hold office until the earlier of the 2029 annual meeting of stockholders, the election of such director’s successor, or such director’s death, resignation or removal;”

Envoy Medical, Inc. reported the fiscal quarter ended March 31, 2026 results: revenue $39.

“Net Revenue was $39 for the three months ended March 31, 2026.”

Envoy Medical, Inc. engaged EisnerAmper LLP as its auditor.

“Upon the approval of the Committee, the Company entered into an engagement agreement with EisnerAmper, dated March 26, 2026, to serve as the Company’s independent public accounting firm for the fiscal year ending December 31, 2026.”

Envoy Medical, Inc. dismissed Grant Thornton LLP as its auditor.

“On March 25, 2026, the Company notified Grant Thornton LLP (“ Grant Thornton ”) of its dismissal as the Company’s independent registered public accounting firm, effective as of the date of the notice.”

Envoy Medical, Inc. reported full year ended December 31, 2025 results: revenue $241.

“Net Revenue was $241 as of December 31, 2025 compared to $225 for year ended December 31, 2024.”

Envoy Medical, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(2), 5815(d)(4)(B)).

“February 23, 2026, Envoy Medical, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Hearings office confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) in compliance with the Nasdaq Hearing Panel’s letter dated October 23, 2025. In addition, pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a discretionary panel monitor for a period of one year from February 12, 2026.”

Envoy Medical, Inc. entered into Pre-Funded Warrants with certain investors valued at 27,053,850 Pre-Funded Warrants to purchase 27,053,850 shares of Common Stock at an exercise price of (effective 2026-02-11).

“ii) 27,053,850 pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase 27,053,850 shares of Common Stock, (iii) 45,000,000 Series A-1 Warrants to purchase 45,000,000 shares of Common Stock and/or pre-funded warrants (the “ Series”

Envoy Medical, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC valued at exclusive placement agent for the Offering (effective 2025-09-17).

“H.C. Wainwright & Co., LLC (“ Wainwright ”) acted as the exclusive placement agent for the Offering pursuant to an Engagement Letter, dated September 17, 2025, as amended on December 17, 2025, February 9, 2026 and February 11, 2026 (the “ Engagement Letter ”).”

Envoy Medical, Inc. entered into Securities Purchase Agreement with certain investors valued at aggregate gross proceeds of approximately $30.0 million from the Offering (effective 2026-02-11).

“On February 11, 2026, Envoy Medical, Inc., a Delaware corporation (the “ Company ”), commenced a best efforts public offering (the “ Offering ”) of an aggregate of (i) 47,946,150 shares (the “ Shares ”) of the Company’s Class A Common Stock, par value $0.0001 per share (“ Common Stock ”), (ii) 27,053,850 pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase 27,053,850 shares of Common Stock, (iii) 45,000,000 Series A-1 Warrants to purchase 45,000,000 shares of Common Stock and/or pre-funded warrants (the “ Series A-1 Warrants ”), and (iv) 75,000,000 Series A-2 Warrants to purchase 75,000,000 shares of Common Stock and/or pre-funded warrants (the “ Series A-2 Warrants ” and, together with the Series A-1 Warrants, the “ Common Warrants ”).”

Envoy Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“November 19, 2025, Envoy Medical, Inc. (the “Company”) received a staff determination notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), informing the Company that its Class A Common Stock, par value $0.0001 per share (the "Common Stock"), has failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing of the Common Stock on The Nasda”

Envoy Medical, Inc. received a nasdaq extension granted notice regarding market value (rules 5550(b)(2)).

“October 23, 2025, the Nasdaq Hearings Panel (the “Panel”) notified Envoy Medical, Inc. (the “Company) that it has granted the Company’s request for an exception to demonstrate compliance with the $35 million market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”) for continued listing through February 23, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events that occur, including any event that may call into question the”

Envoy Medical, Inc. issued up to 225,564 shares of Common Stock of warrant to Placement Agent or its designees for $1.6625 per share.

“Placement Agent Warrants are immediately exercisable, will expire on the earlier of (i) two years from the Effective Date and (ii) October 7, 2030, and have an exercise price of $1.6625 per share. Neither of the Placement Agent Warrants nor the shares of Common Stock issuable upon the exercise of the Placement Agent Warrants (the “Placement Agent Warrant Shares”)”

Envoy Medical, Inc. issued up to an aggregate of 9,022,572 shares of Common Stock of warrant to accredited and institutional investors named therein for $1.33 per share.

“(the “Registered Offering”) 3,007,524 shares (the “Shares”) of Class A common stock, par value $0.0001 per share, of the Company (“Common Stock”), at a purchase price of $1.33 per share. The Shares were offered pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-282474) and a related prospectus supplement filed with”

Envoy Medical, Inc. issued 3,007,524 shares of common stock to accredited and institutional investors named therein for $1.33 per share.

“(the “Registered Offering”) 3,007,524 shares (the “Shares”) of Class A common stock, par value $0.0001 per share, of the Company (“Common Stock”), at a purchase price of $1.33 per share. The Shares were offered pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-282474) and a related prospectus supplement filed with”

Envoy Medical, Inc. issued 5,725,206 shares of Common Stock of warrant to the Purchasers for Issued in connection with the registered direct offering of common stock.

“the Company agreed to issue to the Purchasers warrants (the “Private Warrants”) to purchase up to an aggregate of 5,725,206 shares of Common Stock (the “Warrant Shares”).”

Envoy Medical, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“August 26, 2025, the Company received a determination letter from Nasdaq notifying the Company that it has not regained compliance with the MVLS Requirement within the 180 day cure period. The determination letter informed the Company that it can request a hearing regarding Nasdaq’s determination with a Hearings Panel (the “Panel”) by September 2, 2025 to discuss how the Company believes it will regain compliance and why the Company believes the Hearing Panel should grant an extension. If the Company did not make a request to the Hearings Panel, the trading of the Company’s securities would be”

Envoy Medical, Inc. incurred loan of $5,000,000 with GAT Funding, LLC.

“On June 26, 2025, Envoy Medical, Inc. (the “Company”) drew the remaining $5,000,000 of available principal under the promissory note, dated as of March 6, 2025 (the “Note”), between the Company and GAT Funding, LLC (“GAT”).”

Brent T. Lucas was appointed as principal financial officer at Envoy Medical, Inc..

“The Company’s Chief Executive Officer, Brent T. Lucas, will serve as principal financial officer on an interim basis until a successor Chief Financial Officer is appointed.”

David R. Wells departed as Chief Financial Officer at Envoy Medical, Inc..

“Effective May 16, 2025, David R. Wells ceased serving as Chief Financial Officer of Envoy Medical, Inc.”

Envoy Medical, Inc. incurred loan of up to $10,000,000 with GAT Funding, LLC at 8.0% per annum maturing March 6, 2030.

“Envoy Medical, Inc. (the “Company”) has issued a promissory note, effective as of March 6, 2025 (the “Note”), with a principal amount of up to $10,000,000 to GAT Funding, LLC”

Envoy Medical, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“February 25, 2025, Envoy Medical, Inc. (the “Company”) received a deficiency notification letter (the “Notification Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(2) (the “Rule”) because the market value of the Company’s listed securities did not meet the minimum of $35,000,000 for the period for 31 consecutive business days between January 7, 2025 and February 24, 2025. Pursuant to Nasdaq’s Listing Rules, the Company will return to compliance if the market value of its listed securities exceeds $35,000,000 for t”

Michael Crowe was appointed as Director at Envoy Medical, Inc..

“On June 7, 2024, the Board appointed Michael Crowe to fill the vacancy created by Dr. Haring-Smith’s resignation.”

Whitney Haring-Smith resigned as Director at Envoy Medical, Inc..

“On June 6, 2024, Dr. Whitney Haring-Smith, notified the Company of his decision to resign from the board of directors of the Company (the “Board”) effective immediately.”

Envoy Medical, Inc. reported first quarter ended March 31, 2024 results: revenue $59 thousand.

“forward to the prospect of disrupting the hearing industry with new competition and significant innovation.” Financial Results for the Quarter Ended March 31, 2024 Revenue was $59 thousand compared to $78 thousand for the same period in 2023, the decrease is primarily due to a decrease in the number of battery replacement requests received during the three months”

Envoy Medical, Inc. incurred loan of up to $10,000,000 with GAT Funding, LLC at 8.0% per annum maturing 2029-02-27.

“a Material Definitive Agreement Envoy Medical, Inc. (the “Company”) has issued a promissory note, effective as of February 27, 2024 (the “Note”) with a principal amount of up to $10,000,000 to GAT Funding, LLC (“GAT”), an entity controlled by Glen Taylor, who is a member of the Company’s board of directors and controlling stockholder of the Company. Upon meeting”

Envoy Medical, Inc. entered into Note with GAT Funding, LLC valued at principal amount of up to $10,000,000 (effective 2024-02-27).

“Envoy Medical, Inc. (the “Company”) has issued a promissory note, effective as of February 27, 2024 (the “Note”) with a principal amount of up to $10,000,000 to GAT Funding, LLC (“GAT”)”

Envoy Medical, Inc. reported that prior financial statements should not be relied upon.

“On December 14, 2023, the audit committee (the "Audit Committee") of the board of directors of Envoy Medical, Inc. (the "Company"), after considering the recommendations of management, concluded that the Company's previously issued unaudited interim financial statements included in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 (the "Previous Financial Statements" and such period, the "Affected Period"), should no longer be relied upon.”

Envoy Medical, Inc. engaged Grant Thornton LLP as its auditor.

“On October 20, 2023, the Audit Committee (the "Audit Committee") of the Board of Directors of Envoy Medical, Inc. (the "Company") approved the engagement of Grant Thornton LLP ("Grant Thornton") as the Company's independent registered public accounting firm to audit the Company's consolidated financial statements as of and for the year ending December 31, 2023, effective immediately.”

Envoy Medical, Inc. dismissed WithumSmith+Brown, PC as its auditor.

“on October 20, 2023 (the "Dismissal Date"), the Audit Committee dismissed WithumSmith+Brown, PC ("Withum") as the independent registered public accounting firm for the Company, effective immediately.”

Envoy Medical, Inc.: Company ceased being a shell company as a result of the Business Combination (effective 2023-09-29).

“As a result of the Business Combination, the Company ceased being a shell company.”

Envoy Medical, Inc.: Adopted amended and restated bylaws effective September 29, 2023 (effective 2023-09-29).

“On the Closing Date, in connection with the consummation of the Business Combination, the Company adopted the Second Amended and Restated Certificate of Incorporation (as amended and restated, the “ Charter ”) and amended and restated bylaws (as amended and restated, the “ Bylaws ”).”

Envoy Medical, Inc.: Adopted Second Amended and Restated Certificate of Incorporation effective September 29, 2023, including amendments proposed by Charter Proposals (effective 2023-09-29).

“On the Closing Date, in connection with the consummation of the Business Combination, the Company adopted the Second Amended and Restated Certificate of Incorporation (as amended and restated, the “ Charter ”) and amended and restated bylaws (as amended and restated, the “ Bylaws ”).”

Envoy Medical, Inc. underwent a change of control involving Envoy Medical Corporation for Each share of Envoy Common Stock converted into the right to receive a number of shares of New Envoy Common Stock equal to the Exchange Ratio of 0.063603; Spons (closed 2023-09-29).

“share of Envoy Common Stock was converted into the right to receive pursuant to the applicable provisions of the Business Combination Agreement. The Exchange Ratio was equal to 0.063603. In addition, pursuant to the subscription agreement, dated April 17, 2023 (as amended to date, the “ Subscription Agreement ”), by and between Anzu and Anzu SPAC GP I LLC (the “”

Priya Cherian Huskins resigned as Director at Envoy Medical, Inc..

“each of Diane Dewbrey, Daniel Hirsch and Priya Cherian Huskins resigned as directors”

Daniel Hirsch resigned as other_named_officer at Envoy Medical, Inc..

“each of Whitney Haring-Smith and Daniel Hirsch resigned as executive officers”

Daniel Hirsch resigned as Director at Envoy Medical, Inc..

“each of Diane Dewbrey, Daniel Hirsch and Priya Cherian Huskins resigned as directors”

Diane Dewbrey resigned as Director at Envoy Medical, Inc..

“each of Diane Dewbrey, Daniel Hirsch and Priya Cherian Huskins resigned as directors”

Glen A. Taylor was elected as Director at Envoy Medical, Inc..

“each of Brent Lucas, Charles Brynelsen, Whitney Haring-Smith, Susan J. Kantor, Mona Patel, Janis Smith-Gomez and Glen A. Taylor were elected as directors”

Janis Smith-Gomez was elected as Director at Envoy Medical, Inc..

“each of Brent Lucas, Charles Brynelsen, Whitney Haring-Smith, Susan J. Kantor, Mona Patel, Janis Smith-Gomez and Glen A. Taylor were elected as directors”

Mona Patel was elected as Director at Envoy Medical, Inc..

“each of Brent Lucas, Charles Brynelsen, Whitney Haring-Smith, Susan J. Kantor, Mona Patel, Janis Smith-Gomez and Glen A. Taylor were elected as directors”

Susan J. Kantor was elected as Director at Envoy Medical, Inc..

“each of Brent Lucas, Charles Brynelsen, Whitney Haring-Smith, Susan J. Kantor, Mona Patel, Janis Smith-Gomez and Glen A. Taylor were elected as directors”

Whitney Haring-Smith resigned as other_named_officer at Envoy Medical, Inc..

“each of Whitney Haring-Smith and Daniel Hirsch resigned as executive officers”

Whitney Haring-Smith resigned as Chairman at Envoy Medical, Inc..

“Charles Brynelsen replaced Whitney Haring-Smith as chairman”

Whitney Haring-Smith was elected as Director at Envoy Medical, Inc..

“each of Brent Lucas, Charles Brynelsen, Whitney Haring-Smith, Susan J. Kantor, Mona Patel, Janis Smith-Gomez and Glen A. Taylor were elected as directors”